| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/23/2007 | EP1786786A1 Adamantyl derivates as p2x7 receptor antagonists |
| 05/23/2007 | EP1786779A1 4-arylazo-3,5-diamino-pyrazole compounds and use thereof |
| 05/23/2007 | EP1786778A1 Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors |
| 05/23/2007 | EP1786777A1 Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| 05/23/2007 | EP1786775A1 Dimeric piperidine derivates |
| 05/23/2007 | EP1786774A1 Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 05/23/2007 | EP1786773A1 Isoindolin-1-one derivatives |
| 05/23/2007 | EP1786770A1 N-(1-(2,3-dihydro-1h-inden-5yl) -2-oxo-3-pyrrolidinyl) -sulfonamide derivatives for use as factor xa inhibitors |
| 05/23/2007 | EP1786769A1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 05/23/2007 | EP1786768A1 Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions |
| 05/23/2007 | EP1786766A1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 05/23/2007 | EP1786762A2 Amidine substituted aryl aniline compounds |
| 05/23/2007 | EP1786759A1 Novel derivatives of 3,5-seco-4-norcholestane and use thereof |
| 05/23/2007 | EP1786548A1 GRANULES COMPRISING A ß-LACTAM ANTIBIOTIC |
| 05/23/2007 | EP1786519A1 Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
| 05/23/2007 | EP1786468A1 Composition for promoting vascular smooth muscle relaxation |
| 05/23/2007 | EP1786466A2 Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors |
| 05/23/2007 | EP1786448A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 05/23/2007 | EP1786443A2 Particulate constructs for release of active agents |
| 05/23/2007 | EP1786442A1 Treatment of neurodegenerative diseases by the use of degs inhibitors |
| 05/23/2007 | EP1786441A2 Method and means for enhanced pulmonary drug delivery |
| 05/23/2007 | EP1786440A2 Treatments of refractory cancers using na+/k+-atpase inhibitors |
| 05/23/2007 | EP1786439A2 Methods of activating nkt cells |
| 05/23/2007 | EP1786438A1 Method for increasing the bone mineral density and bone micro-architecture or connectivity of a mammal using n-acylated glucosamines |
| 05/23/2007 | EP1786437A2 Improved ghb compositions |
| 05/23/2007 | EP1786436A2 Method for improving ventilatory efficiency |
| 05/23/2007 | EP1786435A1 Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders |
| 05/23/2007 | EP1786434A1 Insecticidal compositions |
| 05/23/2007 | EP1786433A2 Betulinol derivatives as anti-hiv agents |
| 05/23/2007 | EP1786432A1 Arrangement for the removal of an absorbent article from a stack of absorbent articles |
| 05/23/2007 | EP1786431A2 Improved photosensitizer formulations and their use |
| 05/23/2007 | EP1786430A2 Small molecules that replace or agonize p53 function |
| 05/23/2007 | EP1786429A2 Compositions and methods relating to novel compounds and targets thereof |
| 05/23/2007 | EP1786428A2 Pde5 inhibitor compositions and methods for treating cardiac indications |
| 05/23/2007 | EP1786427A2 Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers |
| 05/23/2007 | EP1786426A1 Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| 05/23/2007 | EP1786425A1 Useful compounds for hpv infection |
| 05/23/2007 | EP1786424A2 Lonidamine analogues and their use in male contraception and cancer treatment |
| 05/23/2007 | EP1786423A1 A pharmaceutical composition for treating ataxia, multiple system atrophy or balance disorders |
| 05/23/2007 | EP1786422A2 Aryl urea derivatives for treating obesity |
| 05/23/2007 | EP1786421A2 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
| 05/23/2007 | EP1786420A1 Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| 05/23/2007 | EP1786419A1 Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| 05/23/2007 | EP1786418A1 Methods of treating proliferative skin diseases using carbazole derivatives |
| 05/23/2007 | EP1786417A2 Novel polymorphs of azabicyclohexane |
| 05/23/2007 | EP1786416A1 Sulpiride derivatives pharmaceutical compositions |
| 05/23/2007 | EP1786415A1 Metabolism-modulating agents and uses therefor |
| 05/23/2007 | EP1786414A2 Novel statin pharmaceutical compositions and related methods of treatment |
| 05/23/2007 | EP1786412A1 Arene ruthenium (ii) compounds and their use in cancer therapy |
| 05/23/2007 | EP1786411A2 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 05/23/2007 | EP1786410A2 The treatment of inflammatory disorders and pain |
| 05/23/2007 | EP1786409A1 Wound healing |
| 05/23/2007 | EP1786408A1 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
| 05/23/2007 | EP1786407A1 Use of vitamin ds to treat kidney disease |
| 05/23/2007 | EP1786405A2 Compounds and methods for controlling alcohol intake |
| 05/23/2007 | EP1786404A2 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
| 05/23/2007 | EP1786403A1 Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 05/23/2007 | EP1786400A2 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 05/23/2007 | EP1786398A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 05/23/2007 | EP1786397A1 Phenytoin formulations, and uses thereof in wound healing |
| 05/23/2007 | EP1786384A1 Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation |
| 05/23/2007 | EP1786359A1 Medical device for delivering biologically active material |
| 05/23/2007 | EP1786265A2 Novel compositions and methods of treatment |
| 05/23/2007 | EP1786264A2 Cationic antiseptic compositions and methods of use |
| 05/23/2007 | EP1730151A4 Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| 05/23/2007 | EP1655055B1 Use of dapsone as a neuroprotector in cerebral infarction |
| 05/23/2007 | EP1651641B1 Nicotinamide derivatives useful as pde4 inhibitors |
| 05/23/2007 | EP1625127B1 Azaindole compounds as kinase inhibitors |
| 05/23/2007 | EP1587584B1 Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 05/23/2007 | EP1585743B1 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
| 05/23/2007 | EP1562923B1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 05/23/2007 | EP1560576A4 Synthesis of oligomeric epicatechin and catechin-derived procyanidins |
| 05/23/2007 | EP1558234B1 Painless injectable compositions containing salt of 2-arylpropionic acids |
| 05/23/2007 | EP1554936B1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 05/23/2007 | EP1551427A4 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| 05/23/2007 | EP1530494B1 A pharmaceutical preparation containing palladium complex compounds |
| 05/23/2007 | EP1480679B1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| 05/23/2007 | EP1442066B1 Compositions comprising chitosan in the form of nano-sized fibres |
| 05/23/2007 | EP1442040B1 Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists |
| 05/23/2007 | EP1427447A4 Improved therapeutic protocols |
| 05/23/2007 | EP1423384B1 Pyridine derivatives as raf kinase inhibitors |
| 05/23/2007 | EP1416929A4 Cancer treatment with gö6976 and its related compounds |
| 05/23/2007 | EP1385548B1 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 05/23/2007 | EP1370550B1 Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same |
| 05/23/2007 | EP1369419B1 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| 05/23/2007 | EP1363885B1 Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof |
| 05/23/2007 | EP1353910B1 Lactam compound |
| 05/23/2007 | EP1296989B1 Polycyclic xanthones as antibiotics |
| 05/23/2007 | EP1265921B1 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 05/23/2007 | EP1257535B1 Substituted pyridine compounds useful for controlling chemical synaptic transmission |
| 05/23/2007 | EP1254895B1 Nitrogenous cyclic compounds and pharmaceutical compositions containing the same |
| 05/23/2007 | EP1238974B1 Heterocycle derivatives and drugs |
| 05/23/2007 | EP1237845B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 05/23/2007 | EP1218368B1 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS |
| 05/23/2007 | EP1196427B1 C-19-halogen-substituted steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 05/23/2007 | EP1185264B1 Process for the production of amorphous atorvastatin calcium |
| 05/23/2007 | EP1181014B1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 05/23/2007 | EP1146788B1 Indomethacin amide derivatives for antiangiogenic and/or antitumorigenic use |
| 05/23/2007 | EP1097141B1 Imidazole derivatives with biphenylsulfonyl substitution, method for preparing them and their use as a drug or diagnostic agent |
| 05/23/2007 | EP1090146B1 Uses of dna-pk |